Open AccessShould Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Author(s) -
Sarah A. Holstein,
Vera J. Suman,
Philip L. McCarthy
Publication year - 2019
Publication title -
current hematologic malignancy reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.299
H-Index - 35
eISSN - 1558-822X
pISSN - 1558-8211
DOI - 10.1007/s11899-019-0495-9
Subject(s) - clinical endpoint , medicine , multiple myeloma , surrogate endpoint , clinical trial , randomized controlled trial , progression free survival , oncology , hematology , overall survival , clinical study design , intensive care medicine
While the traditional gold standard for demonstrating clinical benefit of a therapy has been to show prolongation of overall survival (OS), there are multiple factors which can hinder the use of OS as a primary endpoint in randomized clinical trials (RCTs). Here, we analyze recent myeloma RCTs and evaluate the issues relevant to current and future myeloma RCT design.